20 June 2013
Keywords: Par Pharma, Handa Pharma, Takeda, Dexilant, US ANDA rights
Article | 23 April 2012
USA-based Par Pharmaceutical (NYSE: PRX) has entered into an exclusive acquisition and license agreement with Handa Pharmaceuticals to acquire its ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
23 April 2012
24 April 2012
19 June 2013
© 2013 thepharmaletter.com